araag2/HINT huggingface dataset:
Clinical trial NCT00919984 (phase 2, status: terminated)
Conditions: ovarian neoplasms
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: ip chemotherapy
SMILES: [H][N]([H])([H])[Pt]1(OC(=O)C2(CCC2)C(=O)O1)[N]([H])([H])[H]
Reason stopped: 
    this study stopped due to slow accrual.
  
Eligibility criteria:

        Inclusion criteria:

          1. Age >=20 and <=75

          2. Histologically confirmed epithelial ovarian cancer, primary peritoneal carcinoma,
             tubal cancer

          3. Stage 3 or 4

          4. WBC >= 3500/mm3, ANC >= 1500/mm3, platelet >= 100000/mm3, hemoglobin >= 10 g/dl

          5. Serum creatinine <= upper normal limit * 1.25

          6. Total bilirubin <= 1.5mg/mm3, ALT/AST <= upper normal limit * 3, ALP <= upper normal
             limit * 3

          7. Adequate compliance and geographical closeness which make adequate follow-up possible

          8. GOG performance status 0-2

          9. Anticipated survival >= 3 months

         10. Who agreed to participate in this study and signed on informed consent form

        Exclusion criteria:

          1. History of chemotherapy or radiotherapy on abdomen/pelvis area

          2. Pleural/pericardial effusion, ascites causing respiratory difficulties >= NCI-CTCAE
             grade 2

          3. History of other cancers within 5 years

          4. History of unapproved therapy within 30 days before enrollment

          5. Other serious diseases which could threat the safety of participants or impair the
             ability of participants to complete the participation.
Clinical trial NCT01107444 (phase 2, status: completed)
Conditions: non-small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: docetaxel, ly2181308
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Participants with non-small cell lung cancer with locally or advanced metastatic
             disease(Stage IIIB or IV at entry) not amenable to curative therapy and who have
             progressed after 1 line of chemotherapy

          -  Measureable disease as defined by response evaluation criteria in solid tumors
             (RECIST) version 1.1

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1

          -  Must make available any existing tumor tissue from the primary biopsy

          -  Participants with prior radiation may be eligible if they meet certain criteria

          -  Adequate bone marrow reserve and organ functioning

          -  Women must have a negative pregnancy test and must comply with a highly reliable
             contraceptive method during and for 6 months after the treatment period and must not
             be breastfeeding

          -  Men must comply with a contraceptive regimen during and for 6 months after the
             treatment period

        Exclusion Criteria:

          -  Currently enrolled in or discontinued a clinical trial involving an investigational
             drug/device within the last 30 days. Participants may be permitted to enter treatment
             before the 30 day waiting period in special circumstances

          -  Pregnant or breastfeeding

          -  Serious concomitant systemic disorders that would compromise the safety of the
             participant or the participant's ability to complete the study

          -  Second primary malignancy that could affect compliance with the protocol or
             interpretation of the study results

          -  Known allergy or hypersensitivity to docetaxel, taxanes, LY2181308, oligonucleotides,
             or any component of the formulations

          -  Participants with documented central nervous system or brain metastasis at the time of
             study entry

          -  Pre-existing neuropathy equivalent to a common terminology criteria for adverse
             events(CTCAE)code greater than or equal to 2
Clinical trial NCT01382797 (phase 2, status: completed)
Conditions: opioid-induced constipation
ICD codes: F11.14, F11.181, F11.182, F11.188, F11.19, F11.24, F11.281
Drugs: alks 37, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Are at least 18 years of age at time of consent

          -  Have a body mass index (BMI)of 19 to 35 kg/m2 at screening

          -  Are receiving prescribed opioid medication for the management of chronic, non-cancer
             pain

          -  Meet the criteria of OIC

          -  Agree to use an acceptable method of contraception for the duration of the study

        Exclusion Criteria:

          -  Pregnancy and/or currently breastfeeding

          -  Clinically significant medical condition or illness (other than the condition for
             which the pain medication is being prescribed)

          -  Receiving treatment with opioid therapy for cancer-related pain, abdominal pain,
             scleroderma, and/or for the management of drug addiction

          -  Any gastrointestinal (GI) disorder (other than opioid-induced constipation) or GI
             structural abnormality known to affect bowel transit, produce GI obstruction, or
             contribute to bowel dysfunction

          -  Use of naloxone, Subutex or Suboxone, Revia, Relistor, or Entereg starting 15 days
             before the first study visit following screening until the end of the study

          -  Participation in a clinical trial of a pharmacological agent within 30 days before
             screening
Clinical trial NCT01772368 (phase 2, status: completed)
Conditions: asthma
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: fp mdpi, fs mdpi, advair diskus, albuterol
SMILES: [H][C@@]12C[C@@H](C)[C@](OC(=O)CC)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C, OCC1=C(O)C=CC(=C1)C(O)CNCCCCCCOCCCCC1=CC=CC=C1, CC(C)(C)NCC(O)C1=CC(CO)=C(O)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Written informed consent/assent

          -  General good health

          -  Diagnosis of asthma as defined by the National Institutes of Health (NIH)

          -  A best FEV1 of 40%-85% of the predicted normal value during the screening visit (SV)

          -  Subjects need to demonstrate a ≥ 15% reversibility of FEV1 within 30 minutes following
             4 inhalations of albuterol inhalation aerosol (if required, spacers are permitted for
             reversibility testing) at the SV.

          -  Other inclusion criteria apply

        Exclusion Criteria:

          -  History of life-threatening asthma that is defined for this protocol as an asthma
             episode that required intubation.

          -  Culture-documented or suspected bacterial or viral infection of the upper or lower
             respiratory tract, sinus, or middle ear that is not resolved within 2 weeks prior to
             the SV.

          -  Any asthma exacerbation requiring oral corticosteroids within 3 months of the SV. A
             subject must not have had any hospitalization for asthma within 6 months prior to the
             SV.

          -  Taking long-acting β-agonists within 2 weeks of the SV

          -  Other exclusion criteria apply.
Clinical trial NCT00696007 (phase 2, status: withdrawn)
Conditions: transitional cell carcinoma
ICD codes: C22.0, C4A.9, C7B.1, C4A.0, C4A.31, C4A.51, C4A.8
Drugs: gemcitabine and cisplatin
SMILES: [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]
Reason stopped: 
    study was unable to recruit subjects meeting the study requirements.
  
Eligibility criteria:

        Inclusion Criteria:

          -  ECOG performance status 0-2

          -  Estimated GFR>60

          -  High grade TCC on initial biopsy

          -  Clinical stage T1-T3, Nx, Mx based on the AJCC Classification system

          -  TCC confined to the ureter or renal pelvis

          -  Grade II neuropathy or less

        Exclusion Criteria:

          -  Any other malignancy over the previous five years with a risk of relapse that exceeds
             30%

          -  History of previous cystectomy

          -  Evidence of metastatic disease

          -  History of pelvic irradiation or prior chemotherapy
Clinical trial NCT00471991 (phase 2, status: completed)
Conditions: oral contraceptive
ICD codes: T38.4X1A, T38.4X1D, T38.4X1S, T38.4X2A, T38.4X2D, T38.4X2S, T38.4X3A
Drugs: sh t04769g, ethinyl estradiol / dienogest (sh d00659 af)
SMILES: [H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3
Eligibility criteria:

        Inclusion Criteria:

          -  Healthy female volunteers, aged 18 - 35 years (smokers up to 30 years)

          -  Willingness to apply non-hormonal methods of contraception during the course of the
             study (e.g., condom with spermicide, diaphragm with spermicide)

          -  Confirmation of ovulation during the cycle before treatment

          -  Normal routine blood values

        Exclusion Criteria:

          -  Contraindications for the use of oral contraceptives

          -  Pregnancy, lactation

          -  Simultaneous participation in another clinical study

          -  Considerable overweight
Clinical trial NCT00513513 (phase 2, status: terminated)
Conditions: hiv infections
ICD codes: Z21
Drugs: tmc114 (darunavir) / ritonavir
SMILES: CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)COC1=C(C)C=CC=C1C)CC1=CC=CC=C1
Reason stopped: 
    poor recruitment.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with documented HIV-1 infection

          -  For the first 11 subjects (Panel A), screening plasma HIV-1 viral load is =10000
             copies/mL and <100000 copies/mL

          -  For the second set of 13 patients (Panel B), plasma HIV-1 viral load is =20000
             copies/mL and <500000 copies/mL

          -  Patients with CD4+ cell count above 100 cells/µl

          -  Patients have voluntarily signed the ICF

          -  Patients can comply with the protocol requirements

          -  Patient's general medical condition, in the investigator's opinion, does not interfere
             with the assessments and the completion of the trial.

        Exclusion Criteria:

          -  Presence of any currently active AIDS defining illness (Category C conditions
             according to the CDC Classification System for HIV Infection 1993) with some
             exceptions

          -  Previous or current use of antiretroviral (ARVs/anti-HIV drugs) (including both
             investigational as well as commercially available ARVs indicated for the treatment of
             HIV-infection and ARVs for treatment of hepatitis B infection with anti-HIV activity
             (e.g., adefovir)

          -  Having one of protocol listed 1 PI, NRTI, or NNRTI resistance associated mutation at
             screening

          -  Patients with primary HIV infection

          -  Female patients of childbearing potential without use of effective non-hormonal birth
             control methods or not willing to continue practicing these birth control methods for
             at least 30 days after the end of the treatment period

          -  Any active clinically significant disease (e.g., abnormal heart function,
             pancreatitis, acute viral infection) or findings during screening of medical history
             or physical examination that are expected to compromise the patient's safety or
             outcome in the trial.
Clinical trial NCT01321723 (phase 2, status: completed)
Conditions: postmenopausal osteoporosis
ICD codes: N95.0, N95.2
Drugs: pth analog, placebo, forsteo (teriparatide)
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Healthy postmenopausal women (45-80 years old) with a diagnosis of osteoporosis

        Exclusion Criteria:

          -  Use of estrogen or hormone replacement therapy

          -  Use of bisphosphonates, strontium ranelate or denosumab

          -  Use of parathyroid analogues or other bone metabolic agents

          -  Medical conditions which might alter bone metabolism

          -  Any known clinically significant disease affecting calcium metabolism or history of
             metabolic disorders including Paget's disease, osteogenesis imperfecta, or
             osteomalacia

          -  Impairment of thyroid function
Clinical trial NCT02888990 (phase 2, status: completed)
Conditions: leukemia, lymphoblastic, acute
ICD codes: C91.01, C91.02, C91.00
Drugs: dasatinib
SMILES: CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
Eligibility criteria:

        Inclusion Criteria:

          1. Male or female patients ≥ 55 years

          2. Philadelphia chromosome or BCR-ABL positive acute lymphoblastic leukaemia

          3. Not previously treated except with corticosteroids or single dose vincristine (three
             doses cyclophosphamide accepted but not recommended)

          4. With or without documented CNS involvement

          5. Signed written inform consent

          6. Molecular evaluation for BCR-ABL done

        Exclusion Criteria:

          1. Patients with ECOG status > 2

          2. Patient previously treated with Tyrosine Kinase Inhibitors

          3. Patients with QTc > 470 ms

          4. Heart insufficiency NYHA grade III/IV, LEVF < 50% and or RF < 30%, myocardial
             infarction within the past 6 months prior to study

          5. Active secondary malignancy

          6. Patients with active bacterial, viral or fungal infection

          7. Known infection with HIV, Hepatitis B (except post vaccinal profile) or C

          8. Treatment with any, other investigational agent or participating in another trial
             within 30 days prior to entering this study

          9. Inadequate hepatic functions defined as ASAT or ALAT > 2,5 times the institutional
             upper limit of normal and total bilirubin > 2 fold the institutional upper limit
             unless considered to be due to organ involvement by the leukemia

         10. Concurrent severe diseases which exclude the administration of therapy
Clinical trial NCT00614055 (phase 2, status: completed)
Conditions: diabetes, diabetes mellitus, type 2
ICD codes: E23.2, N25.1, P70.2, O24.92, Z83.3, Z86.32, E10.65, E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: insulin degludec/insulin aspart, insulin degludec/insulin aspart, insulin glargine, metformin
SMILES: [Na+].[Na+].[O-]P([O-])(F)=O, [Na+].[Na+].[O-]P([O-])(F)=O, [Na+].[Na+].[O-]P([O-])(F)=O, CSCC[C@H](N)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Informed consent obtained before any trial-related activities. (Trial-related
             activities are any procedure that would not have been performed during normal
             management of the subject.)

          -  Insulin naïve type 2 diabetes subjects (as diagnosed clinically) for at least 3 months
             (no previous insulin treatment or previous short term insulin treatment maximum 14
             days within the last 3 months)

          -  Treatment with one or two oral anti-diabetic drugs (OADs): metformin, sulfonylurea,
             other insulin secretagogue (e.g. repaglinide, nateglinide), alpha-glucosidase
             inhibitors for at least 2 month at a stable maximum tolerated dose or at least half
             maximum allowed dose according to locally approved summary of product characteristics
             (SPC)

          -  HbA1c, 7.0 - 11.0 % (both inclusive)

          -  Body Mass Index (BMI), 25.0 - 37.0 kg/m^2 (both inclusive)

        Exclusion Criteria:

          -  Metformin contraindication according to local practice

          -  Thiazolidinedione (TZD) treatments within the previous three months prior to Visit 1

          -  Any systemic treatment with products, which in the investigator's opinion could
             interfere with glucose or lipid metabolism (e.g. systemic corticosteroids) within 3
             months prior to randomisation

          -  Subject has a clinically significant, active (during the past 12 months) disease of
             the gastrointestinal, pulmonary, neurological, genitourinary, or haematological system
             that, in the opinion of the investigator, may confound the results of the trial or
             pose additional risk in administering trial product
Clinical trial NCT00575965 (phase 2, status: terminated)
Conditions: waldenstrom's macroglobulinemia
ICD codes: C88.0
Drugs: simvastatin
SMILES: CC1=CC(O)=CC(C)=C1Cl
Reason stopped: 
    slow accrual led to early study termination.
  
Eligibility criteria:

        Inclusion Criteria:

          -  18 years of age or older

          -  Clinicopathological diagnosis of Waldenstrom's macroglobulinemia

          -  Measurable disease

          -  Slowly progressing disease not requiring therapy for at least 3-6 months and who do
             not meet consensus panel criteria for initiation of therapy

          -  ECOG Performance status of 0 or 1

          -  Adequate organ function as defined in the protocol

          -  Patients should agree to avoid grapefruit juice which is a major inhibitor of CYP 3A4

        Exclusion Criteria:

          -  Patients who have had chemotherapy or radiotherapy within 4 weeks prior to entering
             the study, or those who have not recovered from adverse events due to agents
             administered more than four weeks earlier

          -  Patients who have had rituximab within 3 months prior to entering the study

          -  Patients who have taken any Statin in the past

          -  Patients who take cyclosporin, danazol, or gemfibrozil will be excluded

          -  Prior history of rhabdomyolysis

          -  Uncontrolled intercurrent illness including, but not limited to ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             the study requirements

          -  Pregnant or breastfeeding women

          -  HIV-positive

          -  Patients who take verapamil will be excluded

          -  Patients with active or history of liver disease

          -  Patients who consume more than three alcoholic beverages per day
Clinical trial NCT01590888 (phase 2, status: completed)
Conditions: huntington disease
ICD codes: G10
Drugs: pbt2, pbt2, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients who:

               1. Provide signed informed consent in accordance with local regulations.

               2. Have Huntington disease including clinical features of HD and a CAG repeat number
                  ≥ 36.

               3. Have a Total Functional Capacity between 6 and 13, inclusive.

               4. Have cognitive impairment as demonstrated by a MoCA score of ≥ 12.

               5. Are ≥ 25 years of age.

               6. If taking tetrabenazine, have been on a stable dose for at least 3 months.

               7. If female, are either a) of childbearing potential and compliant in using
                  adequate birth control or b) not of childbearing potential.

               8. If male, is either a) of reproductive potential and compliant in using adequate
                  birth control or b) not of reproductive potential.

               9. Have a study partner who is willing to provide consent and spends on average at
                  least two hours a day for at least four days a week with the patient, is fluent
                  in the English language, and who agrees to attend certain study visits and
                  provide accurate information about the patient.

              10. Are able to swallow oral capsules.

              11. Are fluent in the English language for the administration of rating scales and
                  have sufficient visual, hearing and motor skills to complete procedures.

                  Exclusion Criteria:

          -  Patients who:

               1. Have an allergy to PBT2 or its excipients.

               2. Have other known primary neurodegenerative disorders associated with dementia.

               3. Have known dementia syndromes due to non-primary CNS disease.

               4. Have another condition that in the investigator's judgment is resulting in
                  clinically significant cognitive impairment.

               5. In the opinion of the investigator, have any clinically significant uncontrolled
                  medical or psychiatric illness, including history of seizures.

               6. Have clinically significant cardiovascular, hepatic, renal, pulmonary, metabolic
                  or endocrine disease that, in the opinion of the investigator, would interfere
                  with an individual's participation in the study.

               7. Have a calculated creatinine clearance at Screening of <50mL/min.

               8. Have a history of malignancy diagnosed within 2 years of Screening.

               9. Are pregnant or lactating females.
Clinical trial NCT01234779 (phase 2, status: completed)
Conditions: schizophrenia
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9
Drugs: bitopertin [ro4917838], bitopertin [ro4917838], olanzapine, placebo
SMILES: C[C@H](OC1=CC=C(C=C1C(=O)N1CCN(CC1)C1=C(F)C=C(C=N1)C(F)(F)F)S(C)(=O)=O)C(F)(F)F, C[C@H](OC1=CC=C(C=C1C(=O)N1CCN(CC1)C1=C(F)C=C(C=N1)C(F)(F)F)S(C)(=O)=O)C(F)(F)F, CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Adult patients, 18-65 years of age

          -  Diagnosis of schizophrenia (Diagnostic and Statistical Manual of Mental Disorders DSM
             IV-TR)

          -  Acute exacerbation which began within the prior 8 weeks

          -  Female patients must be surgically sterile or post-menopausal, or agree to use
             effective contraception for the duration of the study

        Exclusion Criteria:

          -  Current psychiatric diagnosis other than schizophrenia

          -  Alcohol or substance dependence within 3 months or abuse within 1 month (except for
             nicotine)

          -  Electro-convulsive therapy (ECT) within the prior 6 months

          -  Previous treatment with RO4917838 or another GLYT inhibitor

          -  Current treatment with olanzapine, or previous treatment with intolerability or lack
             of response

          -  Treatment with long-acting injectable antipsychotic within 2 dosing intervals

          -  Treatment with > 2 antipsychotics within 3 months

          -  History of neuroleptic malignant syndrome

          -  Have treatment-resistant schizophrenia as judged by treating physician or have failed
             two trials according to criteria in protocol